BiotechTube
Certara

Certara

CERT
Princeton, United States· Est. 2008

Certara is a leading provider of model-informed drug development (MIDD) solutions, serving over 2,000 biopharmaceutical companies worldwide. The company integrates advanced biosimulation software, scientific expertise, and strategic consulting to reduce development risk, improve decision-making, and accelerate time-to-market for new therapies. With specialized capabilities in therapeutic areas including oncology, rare diseases, and pediatrics, Certara plays a critical role in modernizing drug development through quantitative approaches.

certara.com

CERT · Stock Price

USD 6.253.90 (-38.42%)
Market Cap: $993.1M

Historical price data

AI Company Overview

Certara is a leading provider of model-informed drug development (MIDD) solutions, serving over 2,000 biopharmaceutical companies worldwide. The company integrates advanced biosimulation software, scientific expertise, and strategic consulting to reduce development risk, improve decision-making, and accelerate time-to-market for new therapies. With specialized capabilities in therapeutic areas including oncology, rare diseases, and pediatrics, Certara plays a critical role in modernizing drug development through quantitative approaches.

OncologyRare DiseasesPediatricsNeuroscienceImmunologyInfectious Diseases

Technology Platform

Integrated biosimulation platform combining predictive modeling software, scientific services, and AI tools to accelerate drug development from discovery through market access.

Pipeline

3
3 drugs in pipeline
DrugIndicationStageWatch
Oral administration of 100 mg KH176 twice dailyMitochondrial DiseasesPhase 2
Sonlicromanol + PlaceboMitochondrial DiseasesPhase 2
OMTX705 + Pembrolizumab + OMTX705 + OMTX705 + OMTX705 + Tisl...Advanced Solid TumorPhase 1

Funding History

2
Total raised:$348M
IPO$348MDec 11, 2020
Series AUndisclosedJun 15, 2008

Opportunities

Certara is positioned to capitalize on the growing $8-10 billion biosimulation market, driven by increasing regulatory acceptance of model-informed drug development, expansion into complex therapeutic areas like cell/gene therapy, and the integration of AI across the drug development continuum.
The company's integrated platform approach creates significant cross-selling opportunities across its 2,000+ client base.

Risk Factors

Key risks include client concentration with large pharmaceutical companies, potential regulatory changes impacting service demand, emerging competition from AI/ML startups, integration challenges from historical acquisitions, and economic sensitivity of biopharmaceutical R&D spending.
Talent retention in specialized scientific fields also presents an ongoing challenge.

Competitive Landscape

Certara faces competition from Dassault Systèmes (Simulia, BIOVIA) in simulation software, Schrödinger in computational chemistry, and large CROs like ICON and PAREXEL in services. The company differentiates through its integrated platform combining software, services, and AI, deep regulatory expertise, therapeutic specialization, and scale with the largest installed base in biosimulation.